Literatur
Bae KT, Zhu F, Chapman AB et al (2006) Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 1:64–69
Chang M-Y, Ong ACM (2012) Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects. Nephron Clin Pract 120:c25–c34
Hogan MC, Masyuk TV, Page LJ et al (2010) Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 21:1052–1061
Torres VE, Bankir L, Grantham JJ (2009) A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol 4:1140–1150
Walz G, Budde K, Mannaa M et al (2010) Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363:830–840
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Betzen, C. Tolvaptan mindert die Progression bei ADPKD. Nephrologe 8, 65–66 (2013). https://doi.org/10.1007/s11560-012-0719-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11560-012-0719-7